The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its position within the broader sector now presents questions about potential returns . Copycat versions are eroding market share, causing anxieties that betting on companies closely tied to Viagra's once-dominant influence could be a problematic decision